MedTrace Logo

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

NCT01705223 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2015-05-06

No results posted yet for this study

Summary

This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk of HIV infection. In addition, the effect of different intervals of the prime-boost will be studied.

Conditions

  • AIDS

Interventions

BIOLOGICAL

DNA vaccine

4mg/dose, three doses at week 0,4,8

BIOLOGICAL

DNA vaccine prime with the addition of electroporation

4mg/dose, three doses at week 0,4,8

BIOLOGICAL

rTV boost

at week 16

BIOLOGICAL

rTV boost

at week 24

BIOLOGICAL

rTV boost

at week 32

Sponsors & Collaborators

  • National Center for AIDS/STD Control and Prevention, China CDC

    lead OTHER_GOV

Principal Investigators

  • Hao Wu, M.D. · Beijing YouAn Hospital

  • Tong Zhang, M.D. · Beijing YouAn Hospital

  • Yiming Shao, Ph.D. · NCAIDS, China CDC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-10-31
Completion
2015-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705223 on ClinicalTrials.gov